Biogen at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

Biogen at ASHG 2026 in Montréal: 2 presentations (2 posters).

Organization	ASHG 2026 Attendance
Biogen Cambridge, Massachusetts	1 Scientist, Human Genetics · 1 Principal Scientist
biogen.com\|LinkedIn Public company~7,500 people Biogen develops and commercializes medicines for neurological, immunological, and rare diseases. Biogen reported Q2 2026 total revenue of $2.7 billion, up 3% year over year, with updated full-year guidance. › Biogen reported Q2 2026 total revenue of $2.7 billion, up 3% year over year, with updated full-year guidance. 2026-07 · source Biogen completed its acquisition of Apellis, a leader in complement-driven disease treatments, now a wholly owned subsidiary. 2026-05 · source Biogen elected Maria Freire as chair of its board of directors, a new leadership contact for outreach. 2026-02 · source Source: company newsroom Q2 2026 revenue $2.74B, up 3% › FY2026 non-GAAP diluted EPS guidance is $12.00-$13.00, a modest growth outlook. · 2026-07-29 “Total Revenue $2,736 $2,646 3%. Reported Guidance $12.00 to $13.00.” Source: results release Currently hiring › Source: careers page	Poster Wed Oct 21 2:30 pm Part of Complex Traits and Polygenic Disorders Poster Wednesday Session Colocalization analysis of the LRRK2 locus survival signal in progressive supranuclear palsy using MetaBrain eQTL data Exhibit & Poster Hall · Board 8220W Collaborators: University of Groningen Complex diseasesIdentification of disease genesMulti-omicsNeurodegeneration Poster Fri Oct 23 2:30 pm Part of Complex Traits and Polygenic Disorders Poster Friday Session Genome-wide association of neurofilament light chain (NfL) as a biomarker for disease progression in ALS patients Exhibit & Poster Hall · Board 8257F Collaborators: Utrecht University Genome-wide association studyNeurodegeneration

Organization

ASHG 2026 Attendance

Biogen

Cambridge, Massachusetts

1 Scientist, Human Genetics · 1 Principal Scientist

biogen.com|LinkedIn

Public company~7,500 people

Biogen develops and commercializes medicines for neurological, immunological, and rare diseases.

Biogen reported Q2 2026 total revenue of $2.7 billion, up 3% year over year, with updated full-year guidance.

›

Biogen reported Q2 2026 total revenue of $2.7 billion, up 3% year over year, with updated full-year guidance.

2026-07 · source

Biogen completed its acquisition of Apellis, a leader in complement-driven disease treatments, now a wholly owned subsidiary.

2026-05 · source

Biogen elected Maria Freire as chair of its board of directors, a new leadership contact for outreach.

2026-02 · source

Source: company newsroom

Q2 2026 revenue $2.74B, up 3%

›

FY2026 non-GAAP diluted EPS guidance is $12.00-$13.00, a modest growth outlook. · 2026-07-29

“Total Revenue $2,736 $2,646 3%. Reported Guidance $12.00 to $13.00.”

Source: results release

Currently hiring

›

Source: careers page

Poster

Wed Oct 21
2:30 pm

Part of Complex Traits and Polygenic Disorders Poster Wednesday Session

Colocalization analysis of the LRRK2 locus survival signal in progressive supranuclear palsy using MetaBrain eQTL data

Exhibit & Poster Hall · Board 8220W

Collaborators: University of Groningen

Complex diseasesIdentification of disease genesMulti-omicsNeurodegeneration

Poster

Fri Oct 23
2:30 pm

Part of Complex Traits and Polygenic Disorders Poster Friday Session

Genome-wide association of neurofilament light chain (NfL) as a biomarker for disease progression in ALS patients

Exhibit & Poster Hall · Board 8257F

Collaborators: Utrecht University

Genome-wide association studyNeurodegeneration

Instantly find 20 buyers from Biogen

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American Society of Human Genetics. Submit a correction